Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
← catalyst calendarNCT04862663 · readout in 438 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
893actual
Sites
225
Countries
Argentina, Australia, Belgium +20
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-05-10 | actual | When the study began enrolling |
| Primary completion | 2027-11-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-08-14 | estimated | The whole study's end, after follow-up |
| First posted | 2021-04-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Locally Advanced (Inoperable) or Metastatic Breast Cancer
Interventions
- Drug: Capivasertib
- Drug: Fulvestrant
- Drug: Palbociclib
- Drug: Ribociclib
- Drug: Abemaciclib
Primary outcomes
what the primary-completion date above is the date OFPhase Ib: 1. The number of participants with dose-limiting toxicity, as defined in the protocol.
measured Within the first 28 day cycle.
Phase Ib: 2. The number of participants with treatment-related adverse events.
measured From baseline up to approximately 36 months.
Phase Ib: 3. The number of participants with treatment-related serious adverse events.
measured From baseline up to approximately 36 months.
Phase III: 1. Progression Free Survival (PFS).
measured Up to approximately 47 months.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed